OBJECTIVE: To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome in psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients. METHODS: Fecal samples from PsA/SpA patients pre- and posttreatment with tumor necrosis factor inhibitors (TNFi; n = 15) or an anti-interleukin-17A monoclonal antibody inhibitor (IL-17i; n = 14) underwent sequencing (16S ribosomal RNA, internal transcribed spacer and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n = 5) were analyzed for expression of IL-23/Th17-related cytokines, IL-25/IL-17E-producing cells, and type 2 innate lymphoid cells (ILC2s). RESULTS: There were significant shifts in abundance of specific taxa after treatment with IL-17i compared to TNFi, particularly Clostridiales (P = 0.016) and Candida albicans (P = 0.041). These subclinical alterations correlated with changes in bacterial community co-occurrence, metabolic pathways, IL-23/Th17-related cytokines, and various fatty acids. Ileal biopsies showed that clinically overt CD was associated with expansion of IL-25/IL-17E-producing tuft cells and ILC2s (P < 0.05), compared to pre-IL-17i treatment levels. CONCLUSION: In a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA.
OBJECTIVE: To characterize the ecological effects of biologic therapies on the gut bacterial and fungal microbiome in psoriatic arthritis (PsA)/spondyloarthritis (SpA) patients. METHODS: Fecal samples from PsA/SpA patients pre- and posttreatment with tumor necrosis factor inhibitors (TNFi; n = 15) or an anti-interleukin-17A monoclonal antibody inhibitor (IL-17i; n = 14) underwent sequencing (16S ribosomal RNA, internal transcribed spacer and shotgun metagenomics) and computational microbiome analysis. Fecal levels of fatty acid metabolites and cytokines/proteins implicated in PsA/SpA pathogenesis or intestinal inflammation were correlated with sequence data. Additionally, ileal biopsies obtained from SpA patients who developed clinically overt Crohn's disease (CD) after treatment with IL-17i (n = 5) were analyzed for expression of IL-23/Th17-related cytokines, IL-25/IL-17E-producing cells, and type 2 innate lymphoid cells (ILC2s). RESULTS: There were significant shifts in abundance of specific taxa after treatment with IL-17i compared to TNFi, particularly Clostridiales (P = 0.016) and Candida albicans (P = 0.041). These subclinical alterations correlated with changes in bacterial community co-occurrence, metabolic pathways, IL-23/Th17-related cytokines, and various fatty acids. Ileal biopsies showed that clinically overt CD was associated with expansion of IL-25/IL-17E-producing tuft cells and ILC2s (P < 0.05), compared to pre-IL-17i treatment levels. CONCLUSION: In a subgroup of SpA patients, the initiation of IL-17A blockade correlated with features of subclinical gut inflammation and intestinal dysbiosis of certain bacterial and fungal taxa, most notably C albicans. Further, IL-17i-related CD was associated with overexpression of IL-25/IL-17E-producing tuft cells and ILC2s. These results may help to explain the potential link between inhibition of a specific IL-17 pathway and the (sub)clinical gut inflammation observed in SpA.
Authors: Patrick M Smith; Michael R Howitt; Nicolai Panikov; Monia Michaud; Carey Ann Gallini; Mohammad Bohlooly-Y; Jonathan N Glickman; Wendy S Garrett Journal: Science Date: 2013-07-04 Impact factor: 47.728
Authors: Mary-Ellen Costello; Francesco Ciccia; Dana Willner; Nicole Warrington; Philip C Robinson; Brooke Gardiner; Mhairi Marshall; Tony J Kenna; Giovanni Triolo; Matthew A Brown Journal: Arthritis Rheumatol Date: 2015-03 Impact factor: 10.995
Authors: Alina Soare; Stefanie Weber; Lisa Maul; Simon Rauber; Ana Maria Gheorghiu; Markus Luber; Ismail Houssni; Arnd Kleyer; Gero von Pickardt; Manuel Gado; David Simon; Jürgen Rech; Georg Schett; Jörg H W Distler; Andreas Ramming Journal: J Immunol Date: 2018-01-12 Impact factor: 5.422
Authors: Iain B McInnes; Philip J Mease; Bruce Kirkham; Arthur Kavanaugh; Christopher T Ritchlin; Proton Rahman; Désirée van der Heijde; Robert Landewé; Philip G Conaghan; Alice B Gottlieb; Hanno Richards; Luminita Pricop; Gregory Ligozio; Manmath Patekar; Shephard Mpofu Journal: Lancet Date: 2015-06-28 Impact factor: 79.321
Authors: Di Fan; Laura A Coughlin; Megan M Neubauer; Jiwoong Kim; Min Soo Kim; Xiaowei Zhan; Tiffany R Simms-Waldrip; Yang Xie; Lora V Hooper; Andrew Y Koh Journal: Nat Med Date: 2015-06-08 Impact factor: 53.440
Authors: Harry Sokol; Valentin Leducq; Hugues Aschard; Hang-Phuong Pham; Sarah Jegou; Cecilia Landman; David Cohen; Giuseppina Liguori; Anne Bourrier; Isabelle Nion-Larmurier; Jacques Cosnes; Philippe Seksik; Philippe Langella; David Skurnik; Mathias L Richard; Laurent Beaugerie Journal: Gut Date: 2016-02-03 Impact factor: 23.059
Authors: Georg Schett; Proton Rahman; Christopher Ritchlin; Iain B McInnes; Dirk Elewaut; Jose U Scher Journal: Nat Rev Rheumatol Date: 2022-05-05 Impact factor: 20.543
Authors: Peter Joe; Jose C Clemente; Enrica Piras; David S Wallach; Jessica Robinson-Papp; Emeka Boka; Brooke Remsen; Mharisi Bonner; David Kimhy; Deborah Goetz; Kevin Hoffman; Jakleen Lee; Eugene Ruby; Sarah Fendrich; Oded Gonen; Dolores Malaspina Journal: Schizophr Res Date: 2021-10-06 Impact factor: 4.662
Authors: Anand Kumar; Dana Lukin; Robert Battat; Monica Schwartzman; Lisa A Mandl; Ellen Scherl; Randy S Longman Journal: J Gastroenterol Date: 2020-05-04 Impact factor: 7.527